**Appendix Table O1. Characteristics of eligible studies: NSAIDs in adults with normal cognition**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study****DesignCountry****RoB** | **N=** | **Population****Inclusion****Age (mean)****Sex (% female)****Race (% White)****Education (mean years)****Baseline Cognition** | **Intervention** | **Comparison** | **Outcome** **Timing** | **Outcome** **Domain [Instrument]** |
| ADAPT Group[1-5](#_ENREF_1)RCTUSA10 years[4](#_ENREF_4)High8 yearsMedium5 yearsMedium4 years2008: Medium2007: Medium | 10 years16898 years21175 years20714 years2528 | Adults aged 70+ with normal cognition and at least 1 first-degree relative with AD-like dementia**Age** (median)70-74: 55%75-79: 32%80-84: 11%85+: 2%**Sex** 46%**Race**White: 97%Black: 2%Hispanic: 1%**Education**Less than high school: 4%High school degree: 20%College, no degree: 27%College degree: 19%Postgrad: 30%**Baseline cognition** (median)Adjusted 3MS: 95.0  | Celecoxib (200 mg BID) or naproxen (220 mg BID) | Placebo | 10 years8 years15 years24 years3, 4 | **10 years**Brief Cognitive Test Performance [3MS]Multidomain Neuropsychological Test Performance [Composite: HVLT-R, Informant-Rated Dementia Severity Rating Scale, Digit Span, Naming Supermarkets, RBMT]Executive/Attention/Processing Speed [Digit Span]Memory [HVLT] [RBMT]Language [Generative Verbal Fluency]**8 years**Diagnosis [Alzheimer’s Disease]**5 years**Diagnosis [Alzheimer’s Disease]Biomarker [CSF tau : Ab1-42]**4 years**Diagnosis [Alzheimer’s Disease]Brief Cognitive Test Performance [3MS]Multidomain Neuropsychological Test Performance [Composite: HVLT-R, Informant-Rated Dementia Severity Rating Scale, Digit Span, Naming Supermarkets, RBMT]Executive/Attention/Processing Speed [Digit Span]Memory [HVLT] [RBMT] |
| Small, 2008[6](#_ENREF_6)RCTUSAHigh | 88 | Middle-aged and older volunteers with normal cognition and self-reported age-related memory complaints**Age** 58**Sex** 38%**Race** NR**Education** (mean years)15**Baseline cognition** (median)MMSE: 29.2 | Celecoxib 200 mg or 400 mg QD | Placebo | 1.5 years | Executive/Attention/Processing Speed [TMT A] [TMT B] [DSST] [Stroop Interference Kaplan Version] [F.A.S. Letter Fluency Test]Memory [Buschke Selective Reminding Test Total And Delayed Recall] [WMS Verbal Paired Associations] [BVRT]Language [BNT] [Animal Naming Test]Visuospatial [WAIS-III Block Design Test] [RCFT]] |
| Kang, 2007[7](#_ENREF_7)RCTUSAMedium | 6377 | Normal cognition, women aged 65+ participating in healthy study**Age** 72**Sex** 100% **Race** NR**Education**Licensed vocational or registered nurse/associates degree: 67%Bachelors/masters/doctorate degree: 33%**Baseline cognition** TICS: 34 | Aspirin (100 mg QAD) | Placebo | 10 years  | Brief Cognitive Test Performance [TICS]Multidomain Neuropsychological Test Performance [Composite: TICS, Category Fluency, 10 Words List Immediate And Delayed Recall, EBMT]Memory [Composite: 10 Words List Immediate And Delayed Recall, EBMT] |

3MS=Modified Mini-Mental State Examination; BID=twice daily; EBMT=East Boston Memory Test; mg=milligrams; n=sample size; NP=Neuropsychological; NR=not reported; QAD=every other day; QD=every day; SD=standard deviation; RCT=randomized controlled trial; RBMT= Rivermead Behavioral Memory Test; RCFT=Rey-Osterrieth Complex Figure Test; USA=United States; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale